| Autor: |
Szabo, Zsolt, Mena, Esther, Rowe, Steven, Plyku, Donika, Nidal, Rosa, Eisenberger, Mario, Antonarakis, Emmanuel, Fan, Hong, Dannals, Robert, Chen, Ying, Mease, Ronnie, Vranesic, Melin, Bhatnagar, Akrita, Sgouros, George, Cho, Steve, Pomper, Martin |
| Předmět: |
|
| Zdroj: |
Molecular Imaging & Biology; Aug2015, Vol. 17 Issue 4, p565-574, 10p |
| Abstrakt: |
Purpose: Prostate-specific membrane antigen (PSMA) is a recognized target for imaging prostate cancer. Here we present initial safety, biodistribution, and radiation dosimetry results with [F]DCFPyL, a second-generation fluorine-18-labeled small-molecule PSMA inhibitor, in patients with prostate cancer. Procedures: Biodistribution was evaluated using sequential positron-emission tomography (PET) scans in nine patients with prostate cancer. Time-activity curves from the most avid tumor foci were determined. The radiation dose to selected organs was estimated using OLINDA/EXM. Results: No major radiotracer-specific adverse events were observed. Physiologic accumulation was observed in known sites of PSMA expression. Accumulation in putative sites of prostate cancer was observed (SUV up to >100, and tumor-to-blood ratios up to >50). The effective radiation dose from [F]DCFPyL was 0.0139 mGy/MBq or 5 mGy (0.5 rem) from an injected dose of 370 MBq (10 mCi). Conclusions: [F]DCFPyL is safe with biodistribution as expected, and its accumulation is high in presumed primary and metastatic foci. The radiation dose from [F]DCFPyL is similar to that from other PET radiotracers. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink